STRYKER WKN: 864952 ISIN: US8636671013 Kürzel: SYK Forum: Aktien Thema: Hauptdiskussion

könnte mit an sartorius liegen, die ihre prognose ordentlich gesenkt haben. sind ja auch medizinische ausrüster. charttechnisch sind sie jetzt an einer unterstützung, wenn sie nochmal fällt gehts richtung 240$, dann ggf. auch richtung 230$ ins golden pocket seit juli tief 2022

Wieso den ganzen jahresplus wieder abgegeben?

Oh schwietigkeiten oder wegen i flationsängste?

Stryker’s Pangea Systems Receive FDA Clearance https://finance.yahoo.com/news/stryker-pangea-systems-receive-fda-132000467.html?guccounter=1

Stryker Q2 23 Earnings: - Adj EPS $2.54 (est $2.38) - Rev $5.00B (est $4.82B) - Sees FY Adj EPS $10.25 To $10.45, Saw $10.05 To $10.25

https://www.globenewswire.com/news-release/2023/08/03/2718543/0/en/Stryker-reports-second-quarter-2023-operating-results.html

Vor knapp über ein jahr lag die Aktie bei 244 euro..na ja ziemlich magere Ausbeute.

Einzige Aktie die nicht do gut läuft im moment in meine liste

20%

Sinnlose Frage

Wieviel % steigt die Rendite jährlich hier

👳

Ab wann?

Stryker Non-GAAP EPS of $2.14 beats by $0.13, revenue of $4.8B beats by $240M https://seekingalpha.com/news/3962930-stryker-non-gaap-eps-of-2_14-beats-0_13-revenue-of-4_8b-beats-240m • Stryker press release (NYSE:SYK): Q1 Non-GAAP EPS of $2.14 beats by $0.13. • Revenue of $4.8B (+11.8% Y/Y) beats by $240M. • Organic net sales increased 13.6% in the quarter including 12.9% from increased unit volume and 0.7% from higher prices. MedSurg and Neurotechnology net sales of $2.7 billion increased 11.0% in the quarter and 13.1% in constant currency. Organic net sales increased 12.4% in the quarter including 10.5% from increased unit volume and 1.9% from higher prices. Orthopaedics and Spine net sales of $2.1 billion increased 12.7% in the quarter and 15.1% in constant currency. Organic net sales increased 15.2% in the quarter including 16.0% from increased unit volume partially offset by 0.8% from lower prices. • Expect full year 2023 organic net sales growth to be in the range of 8.0% to 9.0% and expect adjusted net earnings per diluted share to be in the range of $10.05 to $10.25 vs. $10.00 consensus

https://investors.stryker.com/press-releases/news-details/2023/Stryker-reports-first-quarter-2023-operating-results/default.aspx